ARPA-H invests $144M in aging biomarkers; WHO projects doubling of 60+ population by 2050

ARPA-H allocated $144 million in March 2026 for aging biomarker development and anti-aging drug testing, reflecting growing state investment in longevity research. WHO projects the global 60+ population will double to 2.1 billion by 2050, and 80+ will triple to 426 million, underscoring demographic pressures. The piece also highlights the risk of charlatanism in the longevity space, though specific fraudulent claims are not detailed.